Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response

2. november 2026 oppdatert av: Adaxion Therapeutics

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Subcutaneous and Intravenous ADX-001 in Healthy Adult Participants

This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ADX-001 in healthy adult participants

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

ADX-001 is a new investigational medicine being developed to treat inflammatory diseases, such as inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and certain rheumatic diseases, such as psoriatic arthritis.

The purpose of this study is to evaluate the safety and tolerability of ADX-001 in healthy adult volunteers. The study will also examine how the body processes the medicine, how the medicine affects the immune system, and whether the body develops antibodies against the medicine. The results of this study will help determine appropriate doses and dosing schedules for future studies in patients with inflammatory diseases.

Studietype

Intervensjonell

Registrering (Antatt)

88

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Rekruttering
        • CMAX Clinical Research

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Provide informed consent - Be willing and able to sign a consent form after understanding the study and before any study-related procedures are performed.
  • Age - Be a healthy adult male or female aged 18 to 55 years.
  • Body weight and BMI - Have a Body Mass Index (BMI) between 18.0 and 32.0 kg/m². Weigh more than 50 kg and less than 120 kg.
  • For women who can become pregnant - Have a negative pregnancy test before participating.
  • Use highly effective birth control during the study and for 15 months after the last study dose.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

  1. Medical Conditions

    • You have a serious or ongoing health condition affecting the heart, lungs, liver, kidneys, digestive system, hormones, nervous system, immune system, or mental health.
    • You have a history of severe allergic reactions, anaphylaxis, or are allergic to the study drug or its ingredients.
  2. Infections

    • You test positive for HIV, hepatitis B, or hepatitis C.
    • You have tuberculosis (TB), a history of TB, recent close contact with someone who has active TB, or a positive TB screening test.
    • You test positive for COVID-19 before receiving the study drug.
    • You have an active or long-term infection requiring treatment.
    • You have needed antibiotics or other anti-infective treatment within the last month.
    • You were hospitalized or required intravenous (IV) treatment for an infection within the last 3 months.
    • You have a history of certain recurring infections, such as shingles (herpes zoster).
    • You have a fever higher than 37.7°C during screening or within 7 days before dosing.
    • In some cases, minor abnormalities may be accepted if the study doctor considers them not clinically important.

4. Heart and Blood Pressure Problems 5. Previous Medications or Treatments

  • You have previously received medicines that target TNFα or IL-23.

  • You have received other biologic medicines within the last 6 months.

  • You have used medicines that significantly suppress the immune system within the required washout period.

  • You have recently used prescription or over-the-counter medications that could affect study results.

  • You received a live vaccine within the last 12 weeks or any other vaccine within the last 4 weeks.

  • You donated blood, plasma, or platelets too recently before joining the study.

    6. Alcohol or Drug Use. 7. Pregnancy and Reproductive Considerations

  • You are pregnant, breastfeeding, or planning to become pregnant during the study period.

  • You are unwilling to use the required birth control methods.

    8. Participation in Other Research Studies

  • You have recently participated in another clinical trial involving an investigational drug or device.

  • You have previously participated in this study.

    9. Ability to Participate

  • You are unable to understand the study requirements or provide informed consent.

  • You are unable or unwilling to follow study procedures and visit schedules.

    10. Conflict of Interest

  • You are an employee of the study sponsor or investigator, or an immediate family member of one.

    11. Other Safety Concerns

  • The study doctor believes that participating could put your health at risk, prevent you from completing the study, or affect the reliability of the study results.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: SAD Cohort 1-5

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

Eksperimentell: MAD Cohort 6-9

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Incidence and severity of Treatment Emergent Adverse Events (TEAEs) of single and multiple doses of ADX-001 administered by subcutaneous and intravenous injection
Tidsramme: From first dose through Day 365 for participants receiving a single dose and through Day 505 for participants receiving multiple doses.
From first dose through Day 365 for participants receiving a single dose and through Day 505 for participants receiving multiple doses.

Sekundære resultatmål

Resultatmål
Tidsramme
PK Parameters peak concentration (Cmax) - SAD
Tidsramme: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
PK Parameters peak concentration (Cmax) - MAD
Tidsramme: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Area under the concentration-time curve (AUC0-t) - SAD
Tidsramme: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Area under the concentration-time curve (AUC0-t) - MAD
Tidsramme: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Terminal elimination half-life (t1/2) - SAD
Tidsramme: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Terminal elimination half-life (t1/2) - MAD
Tidsramme: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Clearance (CL) - SAD
Tidsramme: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Clearance (CL) - MAD
Tidsramme: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Volume of distribution (Vz) - SAD
Tidsramme: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Volume of distribution (Vz) - MAD
Tidsramme: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Serum concentrations of free CD22L- SAD
Tidsramme: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Serum concentrations of free CD22L- MAD
Tidsramme: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Incidence of treatment-emergent anti-drug antibodies (ADA)
Tidsramme: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Maximum observed serum concentration (Cmax) of ADX-001 by ADA status
Tidsramme: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Minimum observed serum concentration (Cmin) of ADX-001 by ADA status
Tidsramme: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Area under the serum concentration-time curve (AUC0-last) of ADX-001 by ADA status
Tidsramme: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Area under the serum concentration-time curve over the dosing interval (AUCτ) of ADX-001 by ADA status
Tidsramme: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Clearance (CL) of ADX-001 by ADA status
Tidsramme: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Terminal elimination half-life (t½) of ADX-001 by ADA status
Tidsramme: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Incidence of treatment-emergent adverse events by ADA status
Tidsramme: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. oktober 2026

Primær fullføring (Antatt)

29. juli 2027

Studiet fullført (Antatt)

14. desember 2028

Datoer for studieregistrering

Først innsendt

2. oktober 2026

Først innsendt som oppfylte QC-kriteriene

11. oktober 2026

Først lagt ut (Faktiske)

15. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ADX-001-CLN-01

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere